Alergia e Imunologia

Estudo randomizado | Inibição da pré-calicreína no angioedema hereditário.

24 Mar, 2022 | 12:10h

Inhibition of Prekallikrein for Hereditary Angioedema – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

Phase 2 RCT: Prophylactic use of garadacimab in patients with hereditary angioedema.

Evaluation and Management of Angioedema in the Emergency Department

---

Evolução antigênica levará a novas variantes do SARS-CoV-2 com gravidade imprevisível.

22 Mar, 2022 | 11:54h

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity – Nature Reviews Microbiology

 

Comentário no Twitter

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severityhttps://t.co/iFL1AD4q2l@pvmarkov, @ArisKatzourakis & Stilianakis argue that ongoing rapid antigenic evolution is likely to produce new variants that may escape immunity and be more severe. pic.twitter.com/BddNu5DZaq

— Nature Reviews Microbiology (@NatureRevMicro) March 14, 2022

 

---

Revisão sistemática | Estratégias para uso tópico de corticosteroides em crianças e adultos com eczema.

22 Mar, 2022 | 11:33h

Strategies for using topical corticosteroids in children and adults with eczema – Cochrane Library

Resumo: What is the best way to use topical corticosteroids to treat people with eczema? – Cochrane Library

 

Comentário no Twitter

What is the best way to use topical #corticosteroids to treat people with #eczema?
"Generally, stronger topical corticosteroids are probably more effective than weaker preparations". https://t.co/iaH6fzyXL4

Read the latest evidence from @CochraneSkin @CebdNottm pic.twitter.com/f01BO2FyDs

— Cochrane UK (@CochraneUK) March 17, 2022

 

---

Estudo randomizado fase 2 | Uso profilático de garadacimabe em pacientes com angioedema hereditário.

21 Mar, 2022 | 16:08h

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly

---

Seguimento de dados de 2 estudos randomizados | Eficácia e segurança do uso de upadacitinibe em pacientes com dermatite atópica moderada a grave.

21 Mar, 2022 | 15:55h

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials – JAMA Dermatology

---

Outro estudo sugere que a 3ª dose de vacina é necessária para proteger as populações contra a variante Ômicron.

11 Mar, 2022 | 15:13h

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study – The BMJ

Comunicado de imprensa: Third vaccine dose critical for protecting populations against omicron variant – BMJ Newsroom

 

Comentário no Twitter

mRNA vaccines are highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants. But three doses are needed to achieve a similar level of protection against omicron, finds a large US study: https://t.co/YMm176gmby

— The BMJ (@bmj_latest) March 10, 2022

 

---

Estudo randomizado | Glicocorticoide inalatório de demanda reduz exacerbações graves em adultos negros e latinos com asma moderada a grave.

9 Mar, 2022 | 13:56h

Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Patient-centered intervention improved asthma outcomes for Black and Latinx adults – Brigham and Women’s Hospital

---

Dois imunologistas explicam quanto tempo dura a imunidade protetora contra COVID-19 após infecção ou vacinação.

8 Mar, 2022 | 18:34h

How long does protective immunity against COVID-19 last after infection or vaccination? Two immunologists explain – The Conversation

---

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022

 

---

[Preprint] Estudo mostra efetividade significativamente reduzida da vacina da Pfizer em crianças de 5 a 11 anos após o surgimento da variante Ômicron.

1 Mar, 2022 | 15:36h

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant – medRxiv

Comentários:

Pfizer Covid vaccine is less effective in kids 5 to 11, study finds – STAT

Pfizer Covid-19 vaccine effectiveness fell quickly for kids during Omicron surge but still offered some protection against severe disease – CNN

More mask mandates fall as poor COVID vaccine protection noted in young kids – CIDRAP

---